What's better than a growth stock that's performed well in the past? The answer is easy: A growth stock that should perform well in the future. Here's why they chose Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX).
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease. The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.